The validity and reliability of the Turkish version of the 12-item Örebro musculoskeletal screening questionnaire (ÖMSQ-12-TR)

Disabil Rehabil. 2023 Dec;45(25):4288-4295. doi: 10.1080/09638288.2022.2089918. Epub 2022 Jun 25.

Abstract

Purpose: The 12-item Örebro Musculoskeletal Screening Questionnaire (ÖMSQ-12) is a multidimensional questionnaire assessing general musculoskeletal problems. This study aimed to investigate its construct validity and reliability.

Materials and methods: Confirmatory factor analysis (CFA) was performed for construct validity. The Tampa Scale for Kinesiophobia (TSK) and the SF-12 and Pain Numerical Rating Scale (P-NRS) were used for convergent validity. Reliability (ICC), internal consistency (Cronbach's alpha), reproducibility, and known-group validity were assessed. The cut-off value was measured.

Results: A total of n = 378 individuals (aged 35.7 ± 12.4 years, female = 73.3%) with a musculoskeletal problem participated in the study. P-NRS score of the individuals was 5. Results showed that a 3-factor model did fit well under CFA (χ2/df = 2.76 ≤ 3). The questionnaire had good reliability (ICC = 0.865) and internal consistency (α = 0.810). There were no floor or ceiling effects (<%15). Total ÖMSQ-12-TR scores had a correlation with the TSK, SF-12 and P-NRS (r = 0.303-0.609). The AUC for the risk of absenteeism from work was obtained as 0.738 (p < 0.001). The risk of absenteeism was high in individuals with an ÖMSQ-12-TR score of ≥57.5.

Conclusions: The ÖMSQ-12-TR is a valid and reliable questionnaire that can be used in determining the risk of absenteeism in musculoskeletal disorders and is convenient for online use.

Clinical trial number: NCT04723615.

Keywords: Musculoskeletal diseases; absenteeism; musculoskeletal pain; patient reported outcome measures; reliability and validity; risk assessment.

MeSH terms

  • Female
  • Humans
  • Kinesiophobia
  • Musculoskeletal Diseases* / diagnosis
  • Pain*
  • Psychometrics
  • Reproducibility of Results
  • Surveys and Questionnaires

Associated data

  • ClinicalTrials.gov/NCT04723615